ArticleFuture medicinal chemistry2025
Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.
Milan Beljkas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it